NanoCytomics

Executive Summary

NanoCytomics is a San Diego-based diagnostics company developing novel, low-cost, non-invasive cancer tests intended for use in primary care settings. Founded in 2015, the company aims to dramatically improve cancer survival rates by enabling early detection through highly accurate blood-based assays. With a focus on sensitivity and affordability, NanoCytomics targets a major gap in oncology screening—making advanced diagnostics accessible at the point of care. Though still in development, the platform could shift cancer detection paradigms by reducing reliance on expensive imaging and invasive biopsies. The technology is positioned to address high-mortality cancers where early intervention is critical. Execution risk remains given limited public data on funding and clinical validation, but the team's vision aligns with growing demand for decentralized screening solutions. If successful, NanoCytomics could capture significant market share in the primary care diagnostics segment, which is underserved by current liquid biopsy offerings.

Upcoming Catalysts (preview)

• Q1 2027Initiation of first clinical validation study55% success
• Q2 2026Strategic partnership with primary care network40% success
• Q3 2026Closing of Series A funding round50% success